Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 11Gynecologic 5Thoracic 2Sarcoma 2Breast 2Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Sarcoma 2Neoplasms 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma, Ewing 1Prostatic Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Ovarian Carcinosarcoma 1Osteosarcoma 1Neuroblastoma 1Leiomyosarcoma 1Hemangiosarcoma 1

Interventions

Cyclophosphamide 17pembrolizumab 12Doxorubicin 10fludarabine 7Irinotecan 7Blood Specimen Collection 7Temozolomide 6Gemcitabine 6Etoposide 6Radiotherapy 5Ifosfamide 5Carboplatin 5Albumin-Bound Paclitaxel 5tecogalan 4cemiplimab 4Vincristine 4Trabectedin 4Paclitaxel 4Nivolumab 4Filgrastim 4Drug Therapy 4Dexamethasone 4Bevacizumab 4pazopanib 3olaparib 3nilotinib 3dostarlimab 3aflibercept 3Therapeutics 3Taxes 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × niraparib × Sarcoma × Clear all
NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04544995 2026-01-21

Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)

GlaxoSmithKline

Phase 1 Terminated
47 enrolled 43 charts
CNSSarcoma

Neoplasms, Neuroblastoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡